Biogen Acquires New Experimental SMA Therapy BIIB115 From Ionis

Biogen Acquires New Experimental SMA Therapy BIIB115 From Ionis

315506

Biogen Acquires New Experimental SMA Therapy BIIB115 From Ionis

Biogen has exercised an option to acquire BIIB115, an investigational treatment for spinal muscular atrophy (SMA), from Ionis Pharmaceuticals. SMA is a rare genetic condition caused by mutations that lead to abnormally low levels of the survival motor neuron protein, known as SMN. BIIB115, previously called ION306, is an antisense oligonucleotide or ASO that is designed to boost production of this protein. This therapy is conceptually similar to Spinraza (nusinersen), another ASO designed to boost…

You must be logged in to read/download the full post.